Werewolf Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Werewolf is a clinical-stage oncology biotechnology company developing conditionally activated INDUKINE therapeutics using its PREDATOR platform. It has no products approved for sale and reported no product-sales revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Collaboration revenue | $0.7 million | $4.5 million |
| Research and development expense | $12.9 million | $11.7 million |
| General and administrative expense | $5.0 million | $5.0 million |
| Operating loss | $17.2 million | $12.2 million |
| Net loss | $16.2 million | $12.0 million |
| Net loss per share, basic and diluted | $0.39 | $0.34 |
| Cash and cash equivalents at period end | $139.2 million | $134.3 million at Dec. 31, 2023 |
| Restricted cash at period end | $21.0 million | $21.0 million at Dec. 31, 2023 |
| Term-loan principal outstanding | $40.0 million | $40.0 million |
Net cash used in operating activities was $15.3 million, versus $9.9 million a year earlier. Investing activities used $0.1 million. Financing activities provided $20.3 million, principally from the ATM offering; the prior-year period included $40.0 million of term-loan proceeds. Total assets were $177.6 million, total liabilities $60.0 million, and stockholders’ equity $117.6 million. Current assets of $142.3 million exceeded current liabilities of $21.2 million. The filing reports no product-sales margin; operating expenses substantially exceeded collaboration revenue.
Changes versus the prior period
- Revenue fell $3.7 million, primarily because Jazz-related development activity was higher in Q1 2023 in preparation for JZP898’s IND submission.
- R&D expense rose $1.2 million, driven mainly by manufacturing and clinical-trial work for WTX-124 and WTX-330; G&A was essentially flat.
- Net loss widened by $4.2 million. Higher R&D expense and lower collaboration revenue were partly offset by increased interest income and the absence of the prior-year success-payment liability remeasurement loss.
- Werewolf sold 4.17 million shares through its ATM program for approximately $20.1 million net proceeds, increasing period-end shares outstanding to 43.28 million from 39.11 million at year-end.
Outlook, developments, and risks
- Management estimated that cash and cash equivalents, together with the cash effects of the subsequent loan refinancing, would fund operating expenses and capital expenditures through at least the first quarter of 2026. This is based on assumptions that may prove incorrect; management said additional funding will be needed beyond available resources to complete development and commercialization.
- As of the filing, management expected updated interim monotherapy dose-escalation data for WTX-124, dose selection for expansion, and initial combination dose-escalation data in the first half of 2024. Initial WTX-330 Phase 1 data were expected in Q2 2024. WTX-124 and WTX-330 trials were ongoing; the filing cautions that preliminary clinical data may change.
- Management reported FDA alignment on a comparability path for an improved WTX-330 manufacturing process. Jazz had initiated a Phase 1 trial of JZP898; Werewolf continues certain development work under its collaboration.
- Subsequent financing: On May 2, 2024, Werewolf entered into a K2 HealthVentures facility providing up to $60 million of term loans and received $30 million gross at closing ($29.5 million net). It used the net proceeds plus $10.5 million of existing cash to repay the PWB loans in May, releasing the PWB-related $20 million restricted-cash requirement. The new facility matures May 1, 2028, carries a variable rate with a 10.3% minimum, and includes covenants and collateral over substantially all assets other than intellectual property. Up to $30 million of additional tranches are conditional; lenders may convert up to $5 million of principal into common shares under stated terms.
- Key risks include clinical failure or delay, patient enrollment and safety uncertainty, manufacturing and third-party dependence, competition, intellectual-property challenges, and the need for additional capital. Further equity financing could dilute shareholders; debt brings interest, covenants, and collateral risks.
- Management concluded disclosure controls were effective and reported that the previously identified internal-control material weakness had been remediated as of March 31, 2024.
Important facts for investors to verify
- Whether the expected WTX-124 and WTX-330 clinical updates were delivered and how the complete data compare with preliminary findings.
- Post-refinancing cash, restricted-cash release, debt balance, effective borrowing cost, and actual runway versus management’s Q1 2026 estimate.
- Remaining ATM capacity, subsequent share issuance, and potential dilution from equity financing or K2 conversion rights.
- Clinical-trial spending, manufacturing progress, Jazz collaboration activity, and the timing and conditions for any milestone or royalty revenue.
- Continued operation of remediated financial controls and compliance with the new loan’s covenants.